Insmed, Inc. (NASDAQ:INSM – Get Free Report) insider Orlov Nicole Schaeffer sold 101,100 shares of the firm’s stock in a transaction that occurred on Thursday, November 19th. The stock was sold at an average price of $145.26, for a total transaction of $14,685,786.00. Following the sale, the insider owned 41,895 shares of the company’s stock, valued at approximately $6,085,667.70. This represents a 70.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Insmed Stock Down 2.2%
INSM stock traded down $3.13 during trading hours on Friday, hitting $141.33. The company’s stock had a trading volume of 6,215,156 shares, compared to its average volume of 3,061,055. The company has a market capitalization of $31.00 billion, a PE ratio of -50.12 and a beta of 0.83. The stock has a 50 day moving average price of $110.85 and a two-hundred day moving average price of $122.79. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75. The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77.
Insmed (NASDAQ:INSM – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The business had revenue of $524.43 million during the quarter, compared to the consensus estimate of $500.36 million. During the same period in the prior year, the firm earned ($1.75) earnings per share. The business’s quarterly revenue was up 268.4% on a year-over-year basis. On average, equities research analysts expect that Insmed, Inc. will post -1.86 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Virginia Estate & Retirement Planning Advisors Inc. acquired a new stake in Insmed in the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. lifted its position in shares of Insmed by 69.4% during the third quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 143 shares in the last quarter. CX Institutional acquired a new position in shares of Insmed during the third quarter worth approximately $46,000. Harbor Investment Advisory LLC bought a new stake in shares of Insmed during the second quarter valued at approximately $52,000. Finally, Heritage Family Offices LLP bought a new stake in shares of Insmed during the third quarter valued at approximately $60,000.
More Insmed News
Here’s some of the latest news about INSM:
- Positive Sentiment: Reports that Sanofi is weighing a takeover have fueled hopes of a premium offer. One analyst cited a potential takeover value of $170–$210 per share. Insmed shares jump as Sanofi weighs potential takeover Analyst on potential takeover value
- Neutral Sentiment: Coverage highlights a split in analyst views: a transaction could give Sanofi access to Insmed’s drug pipeline, while the acquisition cost could create financial strain. Analysts split on potential deal
- Negative Sentiment: Sanofi’s interest remains reported speculation, not a confirmed offer or agreement. If talks do not progress—or the prospective terms disappoint—some of the takeover-driven optimism could fade. Bloomberg Law report on Sanofi weighing a takeover
Analysts Set New Price Targets
Several research firms have issued reports on INSM. Stifel Nicolaus set a $195.00 price objective on Insmed in a research note on Thursday, October 29th. JPMorgan Chase & Co. lowered their target price on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, August 10th. Roth Capital reiterated a “buy” rating and set a $198.00 target price (down from $212.00) on shares of Insmed in a research report on Tuesday, September 15th. HC Wainwright began coverage on shares of Insmed in a report on Wednesday, November 4th. They set a “buy” rating and a $220.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Insmed in a research report on Thursday, September 24th. They issued a “buy” rating and a $188.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $196.52.
Read Our Latest Research Report on INSM
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
Recommended Stories
- Five stocks we like better than Insmed
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
